A new oncolytic virus therapy (IDOV-Immune) for advanced solid tumors

You may qualify if

• Age ≥ 18 years.
• Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists.
• ECOG performance status ≤ 1.
• Measurable disease per RECIST v1.1.
• Adequate organ and bone marrow function.
• At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures).
• Negative pregnancy test for women of childbearing potential.
• Agreement to use effective contraception during treatment and for 3 months after.
• Ability to provide informed consent and comply with study requirements.

You can't join if

• Prior treatment with an oncolytic virus.
• Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years.
• Active uncontrolled infection requiring systemic treatment.
• History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).
• Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions).
• Active or symptomatic autoimmune disease requiring systemic therapy.
• Active or untreated CNS metastases (unless stable per protocol).
• Significant cardiac disease (e.g., NYHA Class III/IV heart failure).
• Interstitial lung disease or prior pneumonitis requiring steroids.
• Conditions requiring chronic immunosuppressive therapy.
• Severe skin disorders or history of pancreatitis.
• Bleeding disorders or history of recent serious thromboembolic events.
• Any medical or psychiatric condition that could interfere with study participation.